Becker's Healthcare March 20, 2019
In the last two months several pharma giants announced or completed deals to expand their portfolio of gene therapy treatments.
The recent flurry of acquisitions and partnerships reveals that Big Pharma wants in on the fast-growing, potentially lucrative gene therapy market.
A breakdown of recent deals:
1. Pfizer agreed to pay $636 million for a 15 percent stake in Vivet Therapeutics March 20, according to The Wall Street Journal. Vivet’s most-developed therapy is for Wilson disease, a rare liver disorder that causes copper buildup. Unless treated with a liver transplant, the disease is fatal. Pfizer has also made other strides into the gene-editing space. Rather than acquiring the companies outright, the drugmaker has struck partherships that grant it the...
Today's Sponsors
Today's Sponsor